Summary

Overview
The global human immunodeficiency virus type-1 (HIV-1) treatment market reached US$ 39,670.14 million in 2023 and is expected to reach US$ 62,752.56 million by 2031, growing at a CAGR of 5.9% during the forecast period 2024-2031.
HIV-1 is a retrovirus, belonging to a group of heterogeneous, lipid-enveloped RNA viruses. HIV-1 is the most common type of HIV (Human Immunodeficiency Virus) accounting for nearly 95% of the cases. The virus attacks the patient’s immune system by destroying CD4 cells, which play a key role in fighting infections. This can lead to AIDS (Acquired Immune Deficiency Syndrome). The most common treatment option for HIV-1 infection is anti-retroviral therapy (ART) which is a combination of antiretroviral drugs. The major goal of ART therapy is to suppress the HIV replication and delay the progression of the condition into AIDS.
Market Dynamics: Drivers
Rising awareness programs and government initiatives
The Human immunodeficiency virus type-1 (HIV-1) treatment market is expected to be majorly driven by awareness programs and government initiatives. These programs were launched to raise awareness about HIV/AIDS and to promote preventive measures like the use of condoms, regular health checkups, and ART therapy for infected patients. Several governments worldwide, NGOs, and global health organizations have launched campaigns and programs to eradicate the infection in the future. As a part of this eradication process, ART therapy plays a crucial role and is anticipated to gain a role in the forecast period.
For instance, the U.S. Department of Health and Human Services has launched “I am a Work of ART” campaign in June 2022, to end the HIV epidemic in the U.S. This campaign as a part of Ending the HIV Epidemic in the U.S. (EHE) initiative aims to reduce the HIV infections in the U.S. by 90% by 2030.
In November 2023, Northwestern University has launched HIV prevention youth awareness campaign called “PrEP4Teens”. The campaign aims to educate and promote the young people who are sexually active to start taking pre-exposure prophylaxis (PrEP). PrEP are FDA-approved medications that reduce an individual’s chance of getting HIV from sex or injection drug use by as much as 99%.
South African National Aids Council has launched the National Strategic Plan (NSP 2023-2028) with the aim of reducing barriers to accessing health and social services for people living with HIV, TB, and STIs. As a part of this program, the government aims to expand the treatment coverage of HIV patients with WHO-recommended ART drugs.
Moreover, the rising prevalence of the condition, increasing research and development activities are anticipated to majorly drive the market growth in the forecast period.
Restraints
The high cost of treatment can be a restraining factor for the market growth in the forecast period. The patient with human immunodeficiency virus type-1 (HIV-1) treatment must take long-term treatment, which can be expensive for some patient populations. Moreover, HIV-1 is highly stigmatized in many parts of the world, leading many people to hide their diagnosis or not get tested in the first place. This further contributes to the hampering of the global HIV-1 market growth.
For more details on this report - Request for Sample
Segment Analysis
The global human immunodeficiency virus type-1 (HIV-1) treatment market is segmented based on type, treatment type, route of administration, distribution channel, and region.
The combination therapies in the treatment type segment accounted for approximately 46.4% of the global human immunodeficiency virus type-1 (HIV-1) treatment market share
Combination HIV medicines, also known as antiretroviral therapy (ART) or highly active antiretroviral therapy (HAART), are the standard of care for treating HIV-1 infection. The dominance of combination therapies is due to their synergistic effect, ability to achieve viral suppression, improved patient outcomes, convenience, adherence benefits, endorsement from treatment guidelines, and ongoing innovation.
Furthermore, combination therapies are designed to minimize drug interactions, prevent drug resistance, and make treatment safer for patients with coexisting conditions. Combination therapy targets the virus at multiple points in its lifecycle, reducing viral load and preventing the progression of HIV to AIDS and related opportunistic infections. It also enhances immune function, reduces the risk of opportunistic infections, and improves overall quality of life. The use of combination therapies is endorsed by international and national treatment guidelines, reducing pill burden, and ensuring treatment remains effective against drug-resistant strains.
The global health organizations such as WHO, CDC, UN, PAHO have recommened combination therapy as a main stay treatment option for HIV patients. For instance, the Pan American Health Organization (PAHO) states that the standard treatment for HIV/AIDS patients consists of a combination of drugs that have the capability to suppress HIV replication. The combination of drugs is used in order to increase potency and reduce the likelihood of the virus developing resistance. ART reduces mortality and morbidity rates among HIV-infected people, and improves their quality of life.
Geographical Analysis
Middle East and Africa have a significant market share of XX% in the global human immunodeficiency virus type-1 (HIV-1) treatment market.
Africa is the most populous region after Asia-Pacific in the world. The continent has the highest prevalence of HIV and the majority of the global HIV-infected patients are living in Africa. According to the World Health Organization (WHO), nearly 25.6 million HIV cases are reported in Africa till 2022. Among this population, 90% knew their status, 82% were receiving treatment and 76% had suppressed viral loads. An estimated 20.9 million people were receiving antiretroviral therapy in 2022. Below is the number of HIV cases reported till 2022, and the data signifies the highest prevalence in the African region.

Fig: estimated number of patients living with HIV, region wise, Source: WHO, UNAIDS estimates
Moreover, the africa region has almost achieved the 95-95-95 target as compared to any other region globally. UNAIDS has established this 95-95-95 targets, whereby 95% of people with HIV should be diagnosed, 95% of those diagnosed with HIV should be receiving antiretroviral therapy (ART), and 95% of all those receiving ART should achieve viral suppression (VLS). According to WHO, Africa has achieved 90-91-93 target, which is higher than any other region in the world.
Market Segmentation
By Type
• Group M
• Group N
• Group O
• Group P
By Treatment Type
• Combination Therapies
• Protease Inhibitors (PIs)
• Integrase Strand Transfer Inhibitors (INSTIs)
• Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
• Non–nucleoside reverse transcriptase inhibitors (NNRTIs)
• Others
By Route of Administration
• Oral
• Parenteral
• Others
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o South Korea
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major players in the human immunodeficiency virus type-1 (HIV-1) treatment market include Gilead Sciences, Inc., ViiV Healthcare, Janssen Global Services, LLC, Viatris Inc., Merck & Co., Inc., GSK plc., Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, AbbVie. and CELLTRION INC. among others.
Why Purchase the Report?
• To visualize the global human immunodeficiency virus type-1 (HIV-1) treatment market segmentation based on type, treatment type, route of administration, distribution channel, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of human immunodeficiency virus type-1 (HIV-1) treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The global human immunodeficiency virus type-1 (HIV-1) treatment market report would provide approximately 70 tables,67 figures, and 187 Pages.
Target Audience 2024
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

Table of Contents
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Treatment Type
3.3. Snippet by Route of Administration
3.4. Snippet by Distribution Channel
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising awareness programs and government initiatives
4.1.1.2. Rising prevalence of HIV infection
4.1.2. Restraints
4.1.2.1. High cost of treatment
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. PESTEL Analysis
5.7. Patent Analysis
5.8. SWOT Analysis
6. By Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
6.1.2. Market Attractiveness Index, By Type
6.2. Group M*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Group N
6.4. Group O
6.5. Group P
7. By Treatment Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
7.1.2. Market Attractiveness Index, By Treatment Type
7.2. Combination Therapies*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Protease Inhibitors (PIs)
7.4. Integrase Strand Transfer Inhibitors (INSTIs)
7.5. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
7.6. Non–nucleoside reverse transcriptase inhibitors (NNRTIs)
7.7. Others
8. By Route of Administration
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.1.2. Market Attractiveness Index, By Route of Administration
8.2. Oral*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Parenteral
8.4. Others
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacies*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacies
9.4. Online Pharmacies
9.5. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.7.1. The U.S.
10.2.7.2. Canada
10.2.7.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.2. Germany
10.3.6.3. UK
10.3.6.4. France
10.3.6.5. Italy
10.3.6.6. Spain
10.3.6.7. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.2. Brazil
10.4.6.3. Argentina
10.4.6.4. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.6.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.2. China
10.5.6.3. India
10.5.6.4. Japan
10.5.6.5. South Korea
10.5.6.6. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Gilead Sciences, Inc.*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. ViiV Healthcare
12.3. Janssen Global Services, LLC
12.4. Viatris Inc.
12.5. Merck & Co., Inc.
12.6. GSK plc.
12.7. Bristol-Myers Squibb Company
12.8. Boehringer Ingelheim International GmbH
12.9. AbbVie.
12.10. CELLTRION INC.
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us